Neuroblastoma
RecruitingStudy on Stem Cell Transplantation and Immunotherapy with Rituximab, Dinutuximab Beta, and Drug Combination for Patients with High-Risk Relapsed Neuroblastoma
Study on Stem Cell Transplantation and Immunotherapy with Rituximab, Dinutuximab Beta, and Drug Combination for Patients with High-Risk Relapsed Neuroblastoma
- Disease:Neuroblastoma
- Substances:Dinutuximab BetaMelphalan+5
Italy- Participants:0–17 years · 18–64 years
- Substances:Dinutuximab Beta
- Sponsor:IRCCS Istituto Giannina Gaslini




